Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational autologous cell therapy combination consists of umbilical cord blood (CB) and human placental-derived stem cells (HPDSC). Developed by New York Medical College, the therapy is being evaluated for the treatment of severe hypoxic-ischemic encephalopathy (HIE) in neonates. The treatment involves the intravenous infusion of the patient's own cord blood cells and placental stem cells, which are hypothesized to migrate to damaged brain tissue and promote repair through paracrine signaling, anti-inflammatory effects, and potential neural regeneration. A Phase 2 study (NCT02434965) is assessing the safety and feasibility of this combined cell product in neonates with severe HIE.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous cord blood + human placental-derived stem cells.